Aytu to Participate in the Maxim Group Virtual Healthcare Conference

ENGLEWOOD, CO / ACCESSWIRE / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Executive Officer, will participate in a company discussion and host one-on-one meetings with investors at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, taking place virtually from June 20-22, 2023.

Mr. Disbrow will participate in a discussion about the company with Naz Rahman, CFA, Senior Biotechnology Analyst at Maxim Group on June 21, 2023 at 3:00pm ET. Investors can register and watch live on M-Vest. To attend, sign up to become an M-Vest member Click Here to Register. 

To arrange a meeting with management, please contact your Maxim representative or Lytham Partners at [email protected].

About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT^® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT^® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal^® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor^® and Tri-Vi-Flor^®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines, personal care products, and dietary supplements addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com.

Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum or Roger Weiss
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.

You May Also Be Interested In

• Rescheduling Marijuana: The Bet That May Be About To Go Very Wrong
• ACE ROBOTICS Unveils Kairos 3.1 and Expands Its Embodied AI Stack from Data to Deployment at WAIC 2026
• Pudu Robotics Showcases Full Product Portfolio at WAIC 2026, Winning the "Most Investor-Attractive Enterprise" Award